TriNetX
unveiled a conversational AI interface and enhanced API capabilities in January 2026, reducing trial costs and timelines as part of a broader effort to democratize clinical-research analytics.
- Country
- United States
US
Coverage
| US | |
|---|---|
| digital-it | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI clinical-trial patient recruitment | digital-it | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.